Mizuho Securities Sticks to Its Buy Rating for Amgen Inc (AMGN)

By Jason Carr

In a report issued on June 28, Salim Syed from Mizuho Securities reiterated a Buy rating on Amgen Inc (AMGNResearch Report), with a price target of $208. The company’s shares closed on Friday at $184.28.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.5% and a 45.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Neon Therapeutics Inc.

Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $208.92.

See today’s analyst top recommended stocks >>

The company has a one-year high of $210.19 and a one-year low of $166.30. Currently, Amgen Inc has an average volume of 2.86M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.